News

Aquestive Therapeutics plans to provide the agency with information on pharmacokinetic modeling to demonstrate that the desired levels of diazepam exposure can be achieved with dose adjustments.

The platform, dubbed DystoniaNet, was able to identify 3 varieties of focal dystonia in a matter of 0.36 seconds with almost 100% accuracy.

The study investigators noted that a higher gravidity and parity number was not associated with a delay in CIS onset.

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, detail the potential benefit the EpiTRAQ tool has from both a patient and clinician perspective.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine discussed the role amyloid plays in various types of Alzheimer disease and its impact on vascular dysfunction.

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Martina Bebin, MD, professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center, detailed the importance of cannabidiol for treatment of TSC.

Neurology News Network for the week ending September 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

The findings suggest that this insomnia phenotype is a more biologically severe form of the disorder associated with cardiovascular, cerebrovascular, and neurocognitive morbidity.

Markov model analysis showed an average gain of 39 days of disability-free life for every 10 minutes of earlier treatment with EVT.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with David Vossler, MD.

The current perspective on the care of patients and the anticipated developments of the future are detailed in part 3 of this special 3-part multimedia series on the evolution of migraine care.

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.

Notably, no patients received a dose and route consistent with national guidelines.

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Episode 1 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas. [WATCH TIME: 3 minutes]

Patients with lower levels of disability tended to report fatigue as the most impactful symptom in daily life.

The professor of neurology and pediatrics at University of Alabama at Birmingham Epilepsy Center discussed the FDA approval of epidiolex for patients with tuberous sclerosis complex.

The results support continued development in Alzheimer disease and in patients with mid-stage Huntington disease who suffer from greater cognitive deficits.

The positive top-line data from Study 3 revealed that children with Dravet syndrome experienced more than a 60% greater reduction in mean monthly convulsive seizures compared to placebo.

Treatment with ocrelizumab can improve freedom from individual events in patients with relapsing-remitting multiple sclerosis regardless of suboptimal DMT response in the past.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.